Dendritic cell-based platform for cancer therapy. Listed on Harmonic's Hot 25 (Q4 2025 #17); best rank #17 in Q4 2025. Harmonic headcount <10.
Biotech
Current Valuation
Private
PRIVATE
QL Price
$1.1B
0% vs last round
QuantLogix's current estimate for Guardian Bio, published 2026-11-04 — in line with the last disclosed round of $1.1B (2026-09).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$1.1B
2026-09
weight 0.89
How this price has held up
No round has priced for Guardian Bio since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-11-04 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Guardian Bio, 2026-11-04 (d64a82e3e9477b00).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Guardian Bio going public?
No. Guardian Bio is private and has not filed to go public. There is no S-1 on file.
What is Guardian Bio's valuation in 2026?
No confirmed valuation is on record for Guardian Bio. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Guardian Bio filed an S-1?
No public S-1 is on file for Guardian Bio.
Is Guardian Bio publicly traded — can you buy Guardian Bio stock?
No. Guardian Bio is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Guardian Bio on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Employees
<10
Last Round
Pre-seed — $500,000 (Aug 2022)
IPO Status
private
Fundraising Status
Pre-seed · $500,000 · 4y 3mo ago
private1 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Pre-seed
$500,000
Aug 2022
—
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Guardian Bio — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-10-28. Re-checked weekly.
Talent Signal
No public careers page or job board could be found for Guardian Bio as of 2026-10-21. That itself is a datapoint: no open external hiring surface.
Key Executive Moves
INDavid MorrisCOO · 2026-09-20
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Checked the company site and major hosted job boards. Re-checked monthly.
Founders & Key People
Richard BarrettAnanya Zutshi
BiotechOncologyCell Therapy
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.